Centrosome-Mediated Chromosomal Instability and Steroid Hormones as Co factors in Human Papillomavirus-Associated Cervical Carcinogenesis: Small Viruses Help to Answer Big Questions

  • Anette Duensing
  • Stefan Duensing
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 617)

Human papillomaviruses (HPVs) are small DNA tumor viruses that contain a double-stranded genome of only approximately 8,000 base pairs. HPVs infect epithelial tissue and cause benign lesions such as common warts but also malignant and premalignant lesions of the anogenital tract and the oropharynx. Over 200 HPV types have been identified so far. The mucosa-associated high-risk HPV types such as HPV-16 or HPV-18 are intimately associated with squamous cell carcinomas (SCCs) of the uterine cervix, the second-most common cause of cancer-related deaths in women worldwide. High-risk HPVs are also involved in SCCs of the anus, penis, vulva, and a subset of oropharyngeal carcinomas (1). Despite the implementation of screening programs and the successful introduction of prophylactic vaccines (2), HPV-associated diseases remain a global health problem, mostly in medically underserved populations and patients with additional risk factors including immunosuppression or inherited cancer susceptibility syndromes.


Cervical Carcinogenesis Centrosome Amplification Centrosome Duplication Centriole Duplication Daughter Centriole 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zur Hausen, H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Koutsky LA, Ault KA, Wheeler CM, et al. (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645–51.PubMedCrossRefGoogle Scholar
  3. 3.
    Walboomers JM, Jacobs MV, Manos MM, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Longworth MS, Laimins LA (2004) Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68:362–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Munger K, Howley PM (2002) Human papillomavirus immortalization and transformation functions. Virus Res 89:213–28.PubMedCrossRefGoogle Scholar
  6. 6.
    Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495–505.PubMedCrossRefGoogle Scholar
  7. 7.
    Lambert PF, Pan H, Pitot HC, et al. (1993) Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc Natl Acad Sci USA 90:5583–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Veldman T, Horikawa I, Barrett JC, et al. (2001) Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol 75:4467–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Phelps WC, Munger K, Yee CL, et al. (1992) Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J Virol 66:2418–27.PubMedGoogle Scholar
  10. 10.
    Jones DL, Alani RM, Munger K (1997) The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 11:2101–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Funk JO, Waga S, Harry JB, et al. (1997) Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 11:2090–100.PubMedCrossRefGoogle Scholar
  12. 12.
    Nguyen DX, Westbrook TF, McCance DJ (2002) Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest. J Virol 76:619–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Steinmann KE, Pei XF, Stoppler H, et al. (1994) Elevated expression and activity of mitotic regulatory proteins in human papillomavirus-immortalized keratinocytes. Oncogene 9:387–94.PubMedGoogle Scholar
  14. 14.
    Munger K, Baldwin A, Edwards KM, et al. (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:11451–60.PubMedCrossRefGoogle Scholar
  15. 15.
    White AE, Livanos EM, Tlsty TD (1994) Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 8:666–77.PubMedCrossRefGoogle Scholar
  16. 16.
    Duensing S, Lee LY, Duensing A, et al. (2000) The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci USA 97:10002–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Nigg EA (2004) Centrosomes in Development and Disease. Wiley-VCH, Weinheim, Germany.CrossRefGoogle Scholar
  18. 18.
    Plug-Demaggio AW, McDougall JK (2002) The human papillomavirus type 16 E6 oncogene induces premature mitotic chromosome segregation. Oncogene 21:7507–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Thomas JT, Laimins LA (1998) Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint. J Virol 72:1131–7.PubMedGoogle Scholar
  20. 20.
    Thompson DA, Belinsky G, Chang TH, et al. (1997) The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints. Oncogene 15:3025–35.PubMedCrossRefGoogle Scholar
  21. 21.
    Southern SA, Noya F, Meyers C, et al. (2001) Tetrasomy is induced by human papillomavirus type 18 E7 gene expression in keratinocyte raft cultures. Cancer Res 61:4858–63.PubMedGoogle Scholar
  22. 22.
    Elson DA, Riley RR, Lacey A, et al. (2000) Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res 60:1267–75.PubMedGoogle Scholar
  23. 23.
    Bartkova J, Horejsi Z, Koed K, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864–70.PubMedCrossRefGoogle Scholar
  24. 24.
    Li JJ, Weroha SJ, Lingle WL, et al. (2004) Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci USA 101:18123–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Goepfert TM, Adigun YE, Zhong L, et al. (2002) Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res 62:4115–22.PubMedGoogle Scholar
  26. 26.
    Zhou H, Kuang J, Zhong L, et al. (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20:189–93.PubMedCrossRefGoogle Scholar
  27. 27.
    Moodley M, Moodley J, Chetty R, et al. (2003) The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer 13:103–10.PubMedCrossRefGoogle Scholar
  28. 28.
    Monsonego J, Magdelenat H, Catalan F, et al. (1991) Estrogen and progesterone receptors in cervical human papillomavirus related lesions. Int J Cancer 48:533–9.PubMedCrossRefGoogle Scholar
  29. 29.
    von Knebel Doeberitz M, Bauknecht T, Bartsch D, et al. (1991) Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proc Natl Acad Sci USA 88:1411–15.CrossRefGoogle Scholar
  30. 30.
    Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R (1989) Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 70:2227–32.PubMedCrossRefGoogle Scholar
  31. 31.
    Baldwin A, Huh KW, Munger K (2006) Human papillomavirus E7 oncoprotein dysregulates steroid receptor coactivator 1 localization and function. J Virol 80:6669–77.PubMedCrossRefGoogle Scholar
  32. 32.
    Arbeit JM, Howley PM, Hanahan D (1996) Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci USA 93:2930–45.PubMedCrossRefGoogle Scholar
  33. 33.
    Riley RR, Duensing S, Brake T, et al. (2003) Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 63:4862–71.PubMedGoogle Scholar
  34. 34.
    Lingle WL, Barrett SL, Negron VC, et al. (2002) Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 99:1978–83.PubMedCrossRefGoogle Scholar
  35. 35.
    Duensing S (2005) A tentative classification of centrosome abnormalities in cancer. Cell Biol Int 29:352–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Nigg EA (2002) Centrosome aberrations: cause or consequence of cancer progression? Nature Rev Cancer 2:1–11.CrossRefGoogle Scholar
  37. 37.
    Duensing S, Duensing A, Crum CP, et al. (2001) Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. Cancer Res 61:2356–60.PubMedGoogle Scholar
  38. 38.
    Guarguaglini G, Duncan PI, Stierhof YD et al. (2005) The Forkhead-associated domain protein Cep170 interacts with polo-like kinase 1 and serves as a marker for mature centrioles. Mol Biol Cell 16:1095–107.PubMedCrossRefGoogle Scholar
  39. 39.
    Duensing S, Münger K (2003) Human papillomavirus type 16 E7 oncoprotein can induce abnormal centrosome duplication through a mechanism independent of inactivation of retinoblastoma protein family members. J Virol 77:12331–35.PubMedCrossRefGoogle Scholar
  40. 40.
    Duensing A, Liu Y, Tseng M, et al. (2006) Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication. Oncogene 25:2943–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Duensing S, Duensing A, Lee DC, et al. (2004) Cyclin-dependent kinase inhibitor indirubin-3’-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene 23:8206–15.PubMedCrossRefGoogle Scholar
  42. 42.
    Sluder G (2004) Centrosome duplication and its regulation in the higher animal cell. In: Nigg EA (Ed) Centrosomes in Development and Disease. Wiley-VCH, Weinheim, Germany, pp. 167–89.CrossRefGoogle Scholar
  43. 43.
    D’Assoro AB, Busby R, Suino K, et al. (2004) Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint. Oncogene 23:4068–75.PubMedCrossRefGoogle Scholar
  44. 44.
    Tsou MF, Stearns T (2006) Mechanism limiting centrosome duplication to once per cell cycle. Nature 442:947–51.PubMedCrossRefGoogle Scholar
  45. 45.
    Tsou MF, Stearns T (2006) Controlling centrosome number: licenses and blocks. Curr Opin Cell Biol 18:74–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Vidwans SJ, Wong ML, O’Farrell PH (2003) Anomalous centriole configurations are detected in Drosophila wing disc cells upon cdk1 inactivation. J Cell Sci 116:137–43.PubMedCrossRefGoogle Scholar
  47. 47.
    Duensing S, Lee BH, Dal Cin P, et al. (2003) Excessive centrosome abnormalities without ongoing numerical chromosome instability in a Burkitt’s lymphoma. Mol Cancer 2:30.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Anette Duensing
  • Stefan Duensing
    • 1
  1. 1.Molecular Virology ProgramUniversity of Pittsburgh Cancer InstitutePittsburghUSA

Personalised recommendations